One of the major aims of allogeneic haemopoietic stem cell transplantation has been the
effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus …

The implementation of dual T-cell depletion comprising 4.5 mg/kg of antithymocyte globulin
(ATG), post-transplantation cyclophosphamide, and cyclosporine A for reduced-intensity …

In order to evaluate the efficacy of ursodeoxycholic acid (UDCA) in the treatment of Chinese
patients with primary biliary cirrhosis, a short‐term, randomized, double‐blind controlled …

We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and
hematopoietic stem cell transplantation (HSCT)(allogeneic (22), autologous (18)) to …

Purpose This study evaluated whether a prophylaxis strategy directed by the graft-versus-
host disease (GVHD) biomarker might reduce the 100-day incidence of acute GVHD grades …

Recommendations on indications for allogeneic haematopoietic SCT have been presented,
but transplantation techniques remain poorly standardized. Pre-transplant risk factors are …

Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical
stem cell transplantation. There is no consensus on the optimal graft-versus-host disease …

The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …

We determined the efficacy of tocilizumab (TCZ) in preventing grade 2-4 acute graft-versus-
host disease (aGVHD) in patients with acute leukemia or myelodysplasia undergoing …

Incidence of grade II-IV acute graft-versus-host disease (aGVHD) in nonmyeloablative
(NMA) transplant recipients remains high. To date, the ideal prophylaxis regimen, which …